Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab

References

Page 1

	Year	Citations
Nonparametric Estimation from Incomplete Observations Edward L. Kaplan, Paul Meier Journal of the American Statistical Association EngineeringAgingLife PredictionRare Event EstimationMortality Rates	1958	38.7K
1994 Consensus Conference on Acute GVHD Grading. Donna Przepiorka, Daniel Weisdorf, Peyton Martin, PubMed	1995	5.1K
Revised Response Criteria for Malignant Lymphoma Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Journal of Clinical Oncology	2007	4.4K
Bone marrow transplant The Medical Journal of Australia TransplantationMarrow TransplantationBone Marrow FailureBone Marrow TransplantStem Cell Transplantation	1999	3.4K
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Rochelle E. Curtis, Lois B. Travis, Philip A. Rowlings, PubMed	1999	650
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation Ola Landgren, Ethel S. Gilbert, J. Douglas Rizzo, Blood	2009	396
Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia Jan Styczyński, P Reusser, H. Einsele, Bone Marrow Transplantation Hematological MalignancyEbv InfectionsImmunologyHematologyVirology	2008	371
Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Jan Styczyński, Lidia Gil, Gloria Tridello, Clinical Infectious Diseases	2013	246
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation Michael Uhlin, H. Wikell, Mikael Sundin, Haematologica TransplantationMarrow TransplantationAutoimmune DiseaseTransplanted PatientsStem Cell Transplantation	2013	181
Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses Mirosław Majewski, Magdalena Korecka, Joanne Joergensen, Transplantation	2003	156

Page 1